Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Burkitt Lymphoma 19Lymphoma, Large B-Cell, Diffuse 17Multiple Myeloma 15Lymphoma, Non-Hodgkin 13Lymphoma, Follicular 11Lymphoma 11Leukemia, Myeloid, Acute 11Recurrence 10Ovarian Neoplasms 9Lymphoma, B-Cell 9Myelodysplastic Syndromes 8Pancreatic Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Leukemia 7Lymphoma, Mantle-Cell 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Hodgkin Disease 6Hematologic Neoplasms 6Breast Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Leukemia, Myelomonocytic, Chronic 5Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Sarcoma, Ewing 4Sarcoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Osteosarcoma 4Lymphoma, Large-Cell, Anaplastic 4

Interventions

fludarabine 1aldesleukin 1Nivolumab 1Ipilimumab 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Giant Cell Tumor of Bone × Cyclophosphamide × 30 days × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡